CTN webinar: Considerations for utilizing single IRBs within the National Drug Abuse Treatment Clinical Trials Network (CTN).
New regulations have established the expectation of a single Institutional Review Board (sIRB) to provide ethical review of a clinical research study. The measure is designed to maintain appropriate protection of study participants and yet streamline federally-funded research reviews by eliminating redundancy and avoiding unnecessary administrative burden. Accordingly, CTN researchers must understand the considerations to factor into selecting a sIRB for a multi-center study.
This presentation from Julia Collins, MD, Protocol Specialist at the NDAT Clinical Coordinating Center at the Emmes Corporation, will describe such considerations based on experiences and lessons learned from research teams working with a variety of sIRBs on seven CTN clinical studies.
Learning Objectives:
- Describe types of sIRBs and evaluate suitability for ethical reviews of specific trials.
- Define sIRB selection criteria as applied to studies across disease areas and study designs.
- Discuss other factors to consider and effective processes to implement when selecting a sIRB.